

Announcement Concerning a COVID-19 Vaccine Development Partnership with VIDO-InterVac at Dalton Chemical Laboratories, Inc.

Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced today that Dalton Chemical Laboratories, Inc. (Toronto, Canada; “Dalton”), a consolidated subsidiary of Seikagaku, has reached an agreement with the University of Saskatchewan’s Vaccine and Infectious Disease Organization–International Vaccine Centre (“VIDO-InterVac”) on a partnership concerning the manufacture of a COVID-19 vaccine that VIDO-InterVac is developing.

Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s innovative COVID-19 vaccine, to be used in early Phase clinical trials, in Dalton’s state-of-the-art, cGMP Health Canada-approved biopharmaceutical facility. On April 23rd, the Canadian Federal government announced a \$1.1 billion strategy to support COVID-19 vaccine research and clinical trials. VIDO-InterVac has made significant progress in its COVID-19 vaccine development with funding from both the federal government and the Government of Saskatchewan and hopes to initiate clinical trials of its vaccine in the fourth quarter of 2020.

Please refer to the following URL for a press release on the partnership published by Dalton: <https://www.dalton.com/blog/2020/07/28/dalton-partners-vido-intervac-combat-covid-19>

About VIDO-InterVac

To strengthen Canada’s role in responding to infectious diseases, the University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) works with international partners to study human and animal pathogens and develop solutions. With 160 interdisciplinary personnel, over \$200 million in containment infrastructure, and more than four decades of experience, VIDO-InterVac develops vaccines and technologies that protect health. VIDO-InterVac receives operating support from the Government of Canada and Government of Saskatchewan. Visit www.vido.org

About Dalton

Dalton Chemical Laboratories is a leading North American cGMP pharmaceutical organization providing integrated drug discovery, development, and manufacturing services. Dalton is FDA registered and Health Canada approved and brings over 30 years of experience to every project. Dalton delivers fully integrated solutions with an emphasis on speed, flexibility, and quality. The availability of integrated services (drug discovery, formulation and process development, and custom synthesis; cGMP sterile fill/finish of liquids and powders and cGMP API manufacturing; and dosage form manufacturing and Accelerated Stability Testing) all at one location helps Dalton to be adaptable, flexible, and cost-effective.

To learn more about Dalton’s history and capabilities, please visit <https://www.dalton.com>.

Please click the link below to view Dalton’s COVID-19 response:

<https://www.dalton.com/blog/2020/04/03/covid-19>.